Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer

The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial. In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein leve...

Full description

Saved in:
Bibliographic Details
Published inAnnals of surgical oncology Vol. 14; no. 6; pp. 1909 - 1918
Main Authors Davies, Simon R., Watkins, Gareth, Mansel, Robert E., Jiang, Wen G.
Format Journal Article
LanguageEnglish
Published United States Springer Nature B.V 01.06.2007
Subjects
Online AccessGet full text
ISSN1068-9265
1534-4681
DOI10.1245/s10434-007-9376-x

Cover

Abstract The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial. In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes. WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups. WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.
AbstractList The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial. In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes. WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups. WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.
BackgroundThe CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.MethodsIn this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients’ clinical outcomes.ResultsWISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer–related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.ConclusionsWISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.
The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial. In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes. WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups. WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.
The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.BACKGROUNDThe CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes.METHODSIn this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes.WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.RESULTSWISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.CONCLUSIONSWISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.
Author Watkins, Gareth
Jiang, Wen G.
Davies, Simon R.
Mansel, Robert E.
Author_xml – sequence: 1
  givenname: Simon R.
  surname: Davies
  fullname: Davies, Simon R.
– sequence: 2
  givenname: Gareth
  surname: Watkins
  fullname: Watkins, Gareth
– sequence: 3
  givenname: Robert E.
  surname: Mansel
  fullname: Mansel, Robert E.
– sequence: 4
  givenname: Wen G.
  surname: Jiang
  fullname: Jiang, Wen G.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17406949$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1v1DAQhi1URL_4AVyQBRKnho7jr-QIoaUrlbYSII6W40zAVeIsdiJtT_x13N0ipEpwmtHM844sP4dkL0wBCXnB4C0rhTxNDAQXBYAuaq5VsXlCDpjME6Eqtpd7UFVRl0ruk8OUbgGY5iCfkX2mBaha1Afk1wff9xgxzN4O9GyzjpiSnwK1oaM3cfoepjR7R1fjevDOznmV6NTT-QfSprmi53b0wx39hGOLMdFvq883BTvZ1fJke2Xbc-oDvVhGG-j7iDbNtLHBYTwmT3s7JHz-UI_I1_OzL81FcXn9cdW8uyycKGEuGOdcI2rOJbYgAbpat9ArYTnHVgshoGJcMNtVnRDYOatEz0Xv2rKrhWP8iLzZ3V3H6eeCaTajTw6HwQaclmQ0SFmLimfw9SPwdlpiyG8zpVIKalAgM_Xqn1SpuVIl1xl6-QAt7YidWUc_2nhn_vx-BtgOcHFKKWL_FwFzb9jsDJts2NwbNpuc0Y8yzs9bL3O0fvhP8jd2CKa5
CitedBy_id crossref_primary_10_1515_hmbci_2015_0001
crossref_primary_10_5483_BMBRep_2018_51_10_192
crossref_primary_10_1371_journal_pcbi_1003409
crossref_primary_10_1016_j_ejca_2008_08_024
crossref_primary_10_1016_j_tibs_2008_07_006
crossref_primary_10_1186_s13287_017_0579_1
crossref_primary_10_1007_s12079_012_0158_2
crossref_primary_10_1038_nrclinonc_2009_73
crossref_primary_10_3892_or_2015_3709
crossref_primary_10_1002_jbmr_3891
crossref_primary_10_3389_fgene_2020_00502
crossref_primary_10_1172_jci_insight_95824
crossref_primary_10_3390_ijms151121011
crossref_primary_10_1016_j_blre_2008_07_002
crossref_primary_10_1016_j_jbc_2023_102971
crossref_primary_10_18632_oncotarget_13021
crossref_primary_10_1007_s00405_013_2740_5
crossref_primary_10_1186_s12905_025_03608_3
crossref_primary_10_1186_1755_8794_6_S1_S4
crossref_primary_10_3892_ijmm_2015_2390
crossref_primary_10_18632_oncotarget_3358
crossref_primary_10_1186_s12967_024_05364_8
crossref_primary_10_1186_s13046_019_1108_0
crossref_primary_10_1177_1535370221992703
crossref_primary_10_3892_ol_2016_5218
crossref_primary_10_1097_MD_0000000000017604
crossref_primary_10_4143_crt_2017_104
crossref_primary_10_1016_j_cellsig_2016_07_009
crossref_primary_10_1097_MD_0000000000017854
crossref_primary_10_1039_c2ib20053h
crossref_primary_10_1111_pcmr_12194
crossref_primary_10_3389_fgene_2021_649387
crossref_primary_10_1111_coa_13281
crossref_primary_10_1136_jcp_2010_082768
crossref_primary_10_34172_ajmb_2019_08
crossref_primary_10_1002_cre2_301
crossref_primary_10_1016_j_cllc_2014_12_008
crossref_primary_10_1158_0008_5472_CAN_08_1461
crossref_primary_10_1007_s12079_016_0343_9
crossref_primary_10_1007_s12079_016_0345_7
crossref_primary_10_1016_j_intimp_2024_113791
crossref_primary_10_1016_j_jnutbio_2011_03_010
crossref_primary_10_18632_aging_203424
crossref_primary_10_1038_s41423_022_00930_w
crossref_primary_10_4103_1673_5374_155427
crossref_primary_10_1007_s12079_009_0048_4
crossref_primary_10_1002_jcp_28253
crossref_primary_10_3892_or_2013_2909
crossref_primary_10_1186_s12967_019_1769_7
crossref_primary_10_1158_0008_5472_CAN_18_2098
crossref_primary_10_1177_1933719118756749
crossref_primary_10_1186_s12935_021_02116_2
crossref_primary_10_1038_onc_2011_142
crossref_primary_10_3892_ol_2014_2663
crossref_primary_10_1136_jcp_2007_052795
crossref_primary_10_1074_jbc_M111_225755
crossref_primary_10_1038_bjc_2015_285
crossref_primary_10_1016_j_biocel_2015_03_007
crossref_primary_10_1038_srep08686
crossref_primary_10_1093_carcin_bgt373
crossref_primary_10_1097_CAD_0000000000001687
crossref_primary_10_1038_leu_2008_359
Cites_doi 10.1677/erc.1.00825
10.1093/nar/25.12.2516
10.1186/bcr1351
10.1593/neo.03316
10.1053/gast.2001.29570
10.1002/ijc.11302
10.1007/s00384-005-0002-8
10.1136/mp.56.2.80
10.1002/jcp.10315
10.1073/pnas.95.11.6355
10.1158/0008-5472.439.65.2
10.1677/joe.0.1780169
10.1023/B:CLIN.0000017168.83616.d0
10.1186/1475-2867-3-15
10.1245/ASO.2006.05.028
10.1158/1541-7786.MCR-04-0130
10.1186/bcr815
10.1111/j.1365-2559.2005.02104.x
10.1038/bjc.1997.596
10.1245/ASO.2005.10.907
10.1242/jcs.03270
10.1006/bbrc.2001.4584
10.1073/pnas.95.25.14717
10.1016/S0022-5347(05)67869-X
10.1016/S1476-5586(03)80018-0
10.1074/jbc.M210945200
10.1093/molehr/gah028
ContentType Journal Article
Copyright Society of Surgical Oncology 2007
Society of Surgical Oncology 2007.
Copyright_xml – notice: Society of Surgical Oncology 2007
– notice: Society of Surgical Oncology 2007.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
DOI 10.1245/s10434-007-9376-x
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Oncogenes and Growth Factors Abstracts
Oncogenes and Growth Factors Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1534-4681
EndPage 1918
ExternalDocumentID 1282625731
17406949
10_1245_s10434_007_9376_x
Genre Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GroupedDBID ---
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
199
1N0
1SB
203
23M
28-
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2WC
2~H
30V
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
67Z
6J9
6NX
78A
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAPKM
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYXX
AAYZH
ABAKF
ABBBX
ABBRH
ABBXA
ABDBE
ABDZT
ABECU
ABFSG
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABOCM
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFO
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACKNC
ACMDZ
ACMFV
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACSTC
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADHKG
ADIMF
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEAQA
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFEXP
AFHIU
AFJLC
AFKRA
AFLOW
AFOHR
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGQPQ
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AIXLP
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
ATHPR
AVWKF
AXYYD
AYFIA
AZFZN
B-.
BA0
BAWUL
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
C1A
CAG
CCPQU
CITATION
COF
CS3
CSCUP
DDRTE
DIK
DL5
DNIVK
DPUIP
E3Z
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ7
GQ8
GRRUI
GXS
H13
HEOXT
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IH2
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
L7B
LAS
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
OWW
P19
P2P
P9S
PF0
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
WOQ
YFH
YLTOR
Z45
ZMTXR
ZOVNA
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7XB
8FK
ABRTQ
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
PUEGO
ID FETCH-LOGICAL-c420t-13337ee7335eb0500d97b0f64a33eb7444081341ad8d44edca64f34fcb2d94c13
IEDL.DBID 7X7
ISSN 1068-9265
IngestDate Fri Sep 05 12:41:22 EDT 2025
Sat Aug 16 17:21:13 EDT 2025
Sat Aug 23 12:24:57 EDT 2025
Thu Apr 03 06:59:50 EDT 2025
Tue Jul 01 02:08:14 EDT 2025
Thu Apr 24 23:12:14 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c420t-13337ee7335eb0500d97b0f64a33eb7444081341ad8d44edca64f34fcb2d94c13
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
PMID 17406949
PQID 227366237
PQPubID 32486
PageCount 10
ParticipantIDs proquest_miscellaneous_70559483
proquest_journals_2666090605
proquest_journals_227366237
pubmed_primary_17406949
crossref_primary_10_1245_s10434_007_9376_x
crossref_citationtrail_10_1245_s10434_007_9376_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2007-06-01
PublicationDateYYYYMMDD 2007-06-01
PublicationDate_xml – month: 06
  year: 2007
  text: 2007-06-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: New York
PublicationTitle Annals of surgical oncology
PublicationTitleAlternate Ann Surg Oncol
PublicationYear 2007
Publisher Springer Nature B.V
Publisher_xml – name: Springer Nature B.V
References D Xie (9376_CR5) 2001; 61
A Babic (9376_CR30) 1998; 2695
K Van Golen (9376_CR33) 1999; 5
W Jiang (9376_CR23) 2001; 7
M Zoubine (9376_CR32) 2001; 282
N Planque (9376_CR1) 2003; 3
WG Jiang (9376_CR25) 2004; 11
M Nessling (9376_CR11) 2005; 65
L Ye (9376_CR20) 2003; 196
D Pennica (9376_CR6) 1998; 95
S Chappell (9376_CR12) 1997; 76
L Soon (9376_CR8) 2003; 278
Y Zhang (9376_CR14) 2005; 7
T Khor (9376_CR7) 2006; 21
G Davies (9376_CR27) 2006; 29
G Davies (9376_CR28) 2004; 21
T Martin (9376_CR16) 2005; 12
H Mason (9376_CR31) 2004; 10
J King (9376_CR21) 2004; 6
C Parr (9376_CR22) 2004; 14
TA Martin (9376_CR26) 2005; 46
L Thorstensen (9376_CR34) 2001; 121
S Banerjee (9376_CR9) 2005; 3
A Nazarenko (9376_CR18) 1997; 25
S Banerjee (9376_CR10) 2003; 5
S Hanavadi (9376_CR15) 2006; 13
A Leask (9376_CR4) 2006; 119
C Kleer (9376_CR13) 2004; 6
G Davies (9376_CR24) 2000; 163
W Jiang (9376_CR29) 2004; 11
B Perbal (9376_CR3) 2003; 56
W Jiang (9376_CR17) 2003; 9
D Bringstock (9376_CR2) 2003; 178
W Jiang (9376_CR19) 2003; 106
References_xml – volume: 11
  start-page: 781
  year: 2004
  ident: 9376_CR25
  publication-title: Endocr Relat Cancer
  doi: 10.1677/erc.1.00825
– volume: 25
  start-page: 2516
  year: 1997
  ident: 9376_CR18
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/25.12.2516
– volume: 5
  start-page: 2511
  year: 1999
  ident: 9376_CR33
  publication-title: Clin Cancer Res
– volume: 7
  start-page: 1080
  year: 2005
  ident: 9376_CR14
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr1351
– volume: 6
  start-page: 179
  year: 2004
  ident: 9376_CR13
  publication-title: Neoplasia
  doi: 10.1593/neo.03316
– volume: 121
  start-page: 1275
  year: 2001
  ident: 9376_CR34
  publication-title: Gastroenterology
  doi: 10.1053/gast.2001.29570
– volume: 106
  start-page: 752
  year: 2003
  ident: 9376_CR19
  publication-title: Int J Cancer
  doi: 10.1002/ijc.11302
– volume: 14
  start-page: 779
  year: 2004
  ident: 9376_CR22
  publication-title: Int J Mol Med
– volume: 21
  start-page: 291
  year: 2006
  ident: 9376_CR7
  publication-title: Int J Colorectal Dis
  doi: 10.1007/s00384-005-0002-8
– volume: 56
  start-page: 80
  year: 2003
  ident: 9376_CR3
  publication-title: Mol Pathol
  doi: 10.1136/mp.56.2.80
– volume: 196
  start-page: 362
  year: 2003
  ident: 9376_CR20
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.10315
– volume: 11
  start-page: 781
  year: 2004
  ident: 9376_CR29
  publication-title: Endocr Relat Cancer
  doi: 10.1677/erc.1.00825
– volume: 2695
  start-page: 6355
  year: 1998
  ident: 9376_CR30
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.95.11.6355
– volume: 65
  start-page: 439
  year: 2005
  ident: 9376_CR11
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.439.65.2
– volume: 178
  start-page: 169
  year: 2003
  ident: 9376_CR2
  publication-title: J Endocrinol
  doi: 10.1677/joe.0.1780169
– volume: 21
  start-page: 31
  year: 2004
  ident: 9376_CR28
  publication-title: Clin Exp Metastasis
  doi: 10.1023/B:CLIN.0000017168.83616.d0
– volume: 3
  start-page: 15
  year: 2003
  ident: 9376_CR1
  publication-title: Cancer Cell Int
  doi: 10.1186/1475-2867-3-15
– volume: 13
  start-page: 802
  year: 2006
  ident: 9376_CR15
  publication-title: Ann Surg Oncol
  doi: 10.1245/ASO.2006.05.028
– volume: 7
  start-page: 2555
  year: 2001
  ident: 9376_CR23
  publication-title: Clin Cancer Res
– volume: 3
  start-page: 151
  year: 2005
  ident: 9376_CR9
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-04-0130
– volume: 6
  start-page: 478
  year: 2004
  ident: 9376_CR21
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr815
– volume: 46
  start-page: 422
  year: 2005
  ident: 9376_CR26
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2005.02104.x
– volume: 76
  start-page: 1558
  year: 1997
  ident: 9376_CR12
  publication-title: Br J Cancer
  doi: 10.1038/bjc.1997.596
– volume: 12
  start-page: 1
  year: 2005
  ident: 9376_CR16
  publication-title: Ann Surg Oncol
  doi: 10.1245/ASO.2005.10.907
– volume: 119
  start-page: 4803
  year: 2006
  ident: 9376_CR4
  publication-title: J Cell Sci
  doi: 10.1242/jcs.03270
– volume: 61
  start-page: 8917
  year: 2001
  ident: 9376_CR5
  publication-title: Cancer Res
– volume: 282
  start-page: 421
  year: 2001
  ident: 9376_CR32
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.2001.4584
– volume: 95
  start-page: 14717
  year: 1998
  ident: 9376_CR6
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.95.25.14717
– volume: 163
  start-page: 985
  year: 2000
  ident: 9376_CR24
  publication-title: J Urol
  doi: 10.1016/S0022-5347(05)67869-X
– volume: 29
  start-page: 1311
  year: 2006
  ident: 9376_CR27
  publication-title: Int J Oncol
– volume: 5
  start-page: 63
  year: 2003
  ident: 9376_CR10
  publication-title: Neoplasia
  doi: 10.1016/S1476-5586(03)80018-0
– volume: 9
  start-page: 6432
  year: 2003
  ident: 9376_CR17
  publication-title: Clin Can Res
– volume: 278
  start-page: 11465
  year: 2003
  ident: 9376_CR8
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M210945200
– volume: 10
  start-page: 181
  year: 2004
  ident: 9376_CR31
  publication-title: Mol Hum Reprod
  doi: 10.1093/molehr/gah028
SSID ssj0017305
Score 2.1552124
Snippet The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their...
BackgroundThe CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells,...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1909
SubjectTerms Angiogenic Proteins - analysis
Breast - pathology
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - pathology
CCN Intercellular Signaling Proteins
Cell Line, Tumor
Cohort Studies
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Insulin-Like Growth Factor Binding Proteins - analysis
Intercellular Signaling Peptides and Proteins - analysis
Intracellular Signaling Peptides and Proteins - analysis
Lymphatic Metastasis - pathology
Metastases
Neoplasm Staging
Patients
Prognosis
Proto-Oncogene Proteins - analysis
Repressor Proteins
RNA, Messenger - analysis
Statistical analysis
Transcription Factors - analysis
Tumor suppressor genes
Tumor Suppressor Proteins - analysis
Tumors
Wnt protein
Title Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/17406949
https://www.proquest.com/docview/227366237
https://www.proquest.com/docview/2666090605
https://www.proquest.com/docview/70559483
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtAqWX0PTpJE116KlEVNbTOpVmsyEp7LK0Dd2bsfWAQrCT3Q3sLX-9I1m7baHNyQZJttDMaGY0o_kQeu_BFJJBaOJVCARUgCOV8hVxCtw4zVhj0w25yVRdXIkvcznPuTnLnFa52RPTRu16G8_IPzLQswp0tf50c0siaFQMrmYEjcdoN1UuA3bW862_VQLzyhTsVCDTTMkc1GRCxptzggsSz-lAPyuy_lst_cfWTDrn_Bnay8Yi_jxQdx898t1z9GSSw-Ev0P1ZhjcBMb3G43VOau1w0zk8W_QxiQ6G4ss_0sZxHzAYfXg0muIB9QJPfEQFWeIfl99mpDwZnuwkfSW9c_yzw-m4H5_GJPYVHkVmWbxEV-fj76MLkhEViBWMRtx5zrX3mnPpWyopdUa3NCjRcO5bLSL8dKzw1rjKCeGdbZQIXATbMmeELfkrtNP1nX-DsFWmoRV0MMELE5wBT5JZWZW2NRTaCkQ3C1rbXG48ol5c19HtABrUAw3qWDM50qBeF-jDdsjNUGvjoc6HGyrVWeyW9ZZJCnT0j1Zw1ShMjsoCvds2gzjFGEnT-f5uWcfiQkZUvECvB8r_nolOl4TNwYM_PkRPNxmFtDxCO6vFnX8LZsuqPU7MeYx2T8fT2ddfj4_obA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcEG9CC_UBLqgWXttxkgNCdLvVLu2uVtCK3kJiO1KlKml3t2I58Yv4j8zksYAEvfWUSLYTyzP2zHgeH8Arj6pQWOiIe1MUHEWA47HxMXcGzbhIyszWGXKTqRmd6I-n4ekG_OxyYSissjsT64PaVZbuyN9KlLMGZXX0_uKSE2gUOVc7BI2GKw79929osS3ejfeRvK-lPBgeD0a8BRXgVktB0OtKRd5HSoU-F6EQLolyURidKeXzSBMCMxU5y1zstPbOZkYXShc2ly7Rtq_wu7dgU1NCaw8294bT2ae12wK3S1i7Vw2eItKErRtV6pBy9bTSnG4GUSMwfPW3IPyPdltLuYP7cK9VT9mHhp8ewIYvH8LtSeuAfwQ_9ltAFTwYztlw1YbRliwrHZvNKwrbw6Fs_EegOqsKhmomGwymrMHZYBNPOCQL9mX8ecb7u81T7tZfqd8VOytZ7WBgexQ2v2QDYs_5Yzi5keV-Ar2yKv0zYNYkmYixQ1J4nRQuQdtV2jDu2zwR2BaA6BY0tW2Bc8LZOE_J0EEapA0NUqrSTDRIVwG8WQ-5aKp7XNd5q6NS2m70RbpmywC2_9GKxqHAyYkwgJ11M25g8spkpa-uFimVM0p0rAJ42lD-90yiOi05eX7tj3fgzuh4cpQejaeHW3C3i2cU_W3oLedX_gUqTcv8ZcuqDL7e9O74BZKwJGA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcUHmnLdQHuKBadWzHTg4IwW5XXcquVoKKvYXEDwmpSsruViwnfhf_jnEeC0jQW0-JZDuxPDOeGc94PoDnDk2hxEtNnfKeogqwNFUupVahG6c5L0xzQ24yVafn8t08mW_Bz_4uTEir7PfEZqO2tQln5Mcc9axCXa2PfZcVMRuOXl9-pQFAKgRaezSNlkPO3Pdv6L0tX42HSOoXnI9OPg5OaQcwQI3kLMCwC6Gd00IkrmQJYzbTJfNKFkK4UsuAxhwKnhU2tVI6awolvZDelNxm0sQCv3sLbmuBRhWKkp5vfL0YBSdpAq0K9xOuki6gymUSbu1JIWk4I0TbQNH13yrxP3Zuo-9Gu3C3M1TJm5az7sGWq-7DzqQLxT-AH8MOWgW3iAtysu4SaitSVJbMFnVI4MOhZPxHyjqpPUGDkwwGU9IibpCJC4gkS_Jp_GFG46P2yY-arzTvgnypSBNqIG9DAv2KDAKjLh7C-Y0s9iPYrurKPQFiVFawFDtk3snM2wy9WG6SNDZlxrAtAtYvaG66UucBceMiDy4P0iBvaZCHes2BBvk6gpebIZdtnY_rOu_3VMo7kV_mGwaN4OAfregmMpwcSyI43DSjKIf4TFG5-mqZh8JGmUxFBI9byv-eiW4uKGd71_74EHZQJvL34-nZPtzpExtZfADbq8WVe4rW06p81vApgc83LRi_ACpCJyc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+Expression+and+Prognostic+Implications+of+the+CCN+Family+Members+WISP-1%2C+WISP-2%2C+and+WISP-3+in+Human+Breast+Cancer&rft.jtitle=Annals+of+surgical+oncology&rft.au=Davies%2C+Simon+R&rft.au=Watkins%2C+Gareth&rft.au=Mansel%2C+Robert+E&rft.au=Jiang%2C+Wen+G&rft.date=2007-06-01&rft.pub=Springer+Nature+B.V&rft.issn=1068-9265&rft.eissn=1534-4681&rft.volume=14&rft.issue=6&rft.spage=1909&rft_id=info:doi/10.1245%2Fs10434-007-9376-x&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=1282625731
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1068-9265&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1068-9265&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1068-9265&client=summon